• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Life Science Market
    Life Science News
    Life Science Stocks
    • Life Science Market
    • Life Science News
    • Life Science Stocks

    DelMar Pharmaceuticals Conference Call – CEO Jeffrey Bacha on Q2 2016 Results

    Matthew Spizziri
    Feb. 24, 2016 11:30AM PST
    Life Science Investing News
    OTCQX:DMPI

    On February 17, 2016 DelMar Pharmaceuticals (OTCQX:DMPI) hosted a business update Conference Call and Webcast, to discuss the Company’s finance results for the Second Quarter of the 2016 Fiscal Year Ending December 31, 2015 and business outlook for 2016.

    On February 17, 2016 DelMar Pharmaceuticals (OTCQX:DMPI) hosted a business update Conference Call and Webcast, to discuss the Company’s finance results for the Second Quarter of the 2016 Fiscal Year Ending December 31, 2015 and business outlook for 2016.
    Listen to the Full Conference Call
    DelMar Pharmaceuticals CEO, Jeffrey Bacha, stated:

    To date, we’re very pleased that we have five U.S. patents and four international patents that have issued so far, which gives pattern protection in United States into 2033. The benefit there of certainly trumping the seven-year to 10-year market exclusivity available to us from orphan drug protection, as well. But the value of the portfolio and the size of it has grown underneath those eight separate patents families.
    So we now have 90 patents moving through the system internationally and four provisional patents pending that were filed in the last 12 months. So you can see that this pattern portfolio is becoming very robust and we expect to bear some very solid fruit that goes along side of the orphan drug protection that we have been granted from the FDA.
    So VAL-083 and GBM, yes there’s historical clinical activity in the indication, but the real driver of our excitement here is the fact that the mechanism is different and distinct from those other chemotherapy agents that have shown promise and have been approved in the treatment of the disease. And specifically VAL-083 gets around the activity of a repair enzyme called MGMT, which is correlated with poor patient outcomes in the disease.
    The goal here is of course on one hand to get this drug VAL-083 into the hands of clinicians as an approved product for the refractory GBM patients as quickly as possible. There is nothing available for these patients. But the real story and the real goal for the company is not to treat patients that are – has failed Avastin, but it’s really to provide an alternative to temozolomide in the newly diagnosed glioblastoma population in the high expressing MGMT population.

    Listen to the Full Conference Call

    otcqx:dmpidelmar pharmaceuticalsconference callunited statesorphan drug
    The Conversation (0)

    Go Deeper

    AI Powered
    Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

    Top 5 Small-cap Pharma Stocks of 2025

    Microscopic view of stem cells.

    Stem Cell Stocks: 10 Biggest NASDAQ Companies in 2025

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×